Dr Khan interviews Dr. Julia Moore-Vogel, Scripps Researcher and lead scientist of the new study using tirzepatide to treat Long COVID. The study is called LoCITT-T, and it is actively enrolling participants. They discuss the study's design, eligibility criteria, and the potential benefits of the drug. Julia shares her personal experience with long COVID and how it has influenced her work. The conversation also covers the importance of making clinical trials accessible to those with disabilities and the innovative use of wearable technology in the study.

Keywords

Long COVID, tirzepatide, clinical trial, disability, wearable technology

Resources:

Long COVID Treatment Trial-Tirzepatide (LoCITT-T): https://www.longcovid.scripps.edu

Fatigue Severity Scale: https://www.med.upenn.edu/cbti/assets/user-content/documents/Fatigue%20Severity%20Scale%20(FSS).pdf

FUN-CAP 27: https://batemanhornecenter.org/wp-content/uploads/2023/12/FUNCAP27-questionnaire.pdf

DSQ-COVID: https://www.researchgate.net/publication/360476212_DePaul_Symptom_Questionnaire-COVID

Eric Topol, MD Ground Truths: https://erictopol.substack.com/

All of Us Research Hub: https://www.researchallofus.org/

Support the show

Subscribe for free written summaries of each episode, resources, and more. LongCovidMD.substack.com/subscribe

Support by donating at BuyMeACoffee

61. Inside The New Long COVID GLP-1 Study